BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34922264)

  • 1. Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment.
    Ditto A; De Cecco L; Paolini B; Alberti P; Martinelli F; Leone Roberti Maggiore U; Bogani G; Chiodini P; Pignata S; Tomassetti A; Raspagliesi F; Mezzanzanica D; Bagnoli M
    Eur J Cancer; 2022 Jan; 161():55-63. PubMed ID: 34922264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
    Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
    Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Evidence of the miRNA-Based Ovarian Cancer Signature MiROvaR in Independent Datasets.
    De Cecco L; Bagnoli M; Chiodini P; Pignata S; Mezzanzanica D
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33801595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimally invasive surgical staging for early stage ovarian cancer: A long-term follow up.
    Gallotta V; Jeong SY; Conte C; Trozzi R; Cappuccio S; Moroni R; Ferrandina G; Scambia G; Kim TJ; Fagotti A
    Eur J Surg Oncol; 2021 Jul; 47(7):1698-1704. PubMed ID: 33573854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment.
    Calura E; Paracchini L; Fruscio R; DiFeo A; Ravaggi A; Peronne J; Martini P; Sales G; Beltrame L; Bignotti E; Tognon G; Milani R; Clivio L; Dell'Anna T; Cattoretti G; Katsaros D; Sartori E; Mangioni C; Ardighieri L; D'Incalci M; Marchini S; Romualdi C
    Ann Oncol; 2016 Aug; 27(8):1511-9. PubMed ID: 27194815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic variants and expression of the TIM-3 gene are associated with clinical prognosis in patients with epithelial ovarian cancer.
    Wu JL; Zhao J; Zhang HB; Zuo WW; Li Y; Kang S
    Gynecol Oncol; 2020 Oct; 159(1):270-276. PubMed ID: 32694063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.
    Marchini S; Cavalieri D; Fruscio R; Calura E; Garavaglia D; Fuso Nerini I; Mangioni C; Cattoretti G; Clivio L; Beltrame L; Katsaros D; Scarampi L; Menato G; Perego P; Chiorino G; Buda A; Romualdi C; D'Incalci M
    Lancet Oncol; 2011 Mar; 12(3):273-85. PubMed ID: 21345725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
    Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
    J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditional disease-free survival rates and their associated determinants in patients with epithelial ovarian cancer: A 15-year retrospective cohort study.
    Ebrahimi V; Khalafi-Nezhad A; Ahmadpour F; Jowkar Z
    Cancer Rep (Hoboken); 2021 Dec; 4(6):e1416. PubMed ID: 33949809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients.
    Bagnoli M; De Cecco L; Granata A; Nicoletti R; Marchesi E; Alberti P; Valeri B; Libra M; Barbareschi M; Raspagliesi F; Mezzanzanica D; Canevari S
    Oncotarget; 2011 Dec; 2(12):1265-78. PubMed ID: 22246208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.
    García-Sáenz JA; Custodio A; Casado A; Vidart JA; Coronado PJ; Martín M; López-Tarruella S; Puente J; Fernández C; Díaz-Rubio E
    Clin Transl Oncol; 2011 Feb; 13(2):121-32. PubMed ID: 21324801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative Network Analysis Reveals a MicroRNA-Based Signature for Prognosis Prediction of Epithelial Ovarian Cancer.
    Li L; Gu H; Chen L; Zhu P; Zhao L; Wang Y; Zhao X; Zhang X; Zhang Y; Shu P
    Biomed Res Int; 2019; 2019():1056431. PubMed ID: 31275959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific Regions, Rather than the Entire Peritoneal Carcinosis Index, are Predictive of Complete Resection and Survival in Advanced Epithelial Ovarian Cancer.
    Rosendahl M; Harter P; Bjørn SF; Høgdall C
    Int J Gynecol Cancer; 2018 Feb; 28(2):316-322. PubMed ID: 29324538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study.
    Martini P; Paracchini L; Caratti G; Mello-Grand M; Fruscio R; Beltrame L; Calura E; Sales G; Ravaggi A; Bignotti E; Odicino FE; Sartori E; Perego P; Katsaros D; Craparotta I; Chiorino G; Cagnin S; Mannarino L; Ceppi L; Mangioni C; Ghimenti C; D'Incalci M; Marchini S; Romualdi C
    Clin Cancer Res; 2017 May; 23(9):2356-2366. PubMed ID: 27827314
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
    Chambers LM; Kuznicki M; Yao M; Chichura A; Gruner M; Reizes O; Debernardo R; Rose PG; Michener C; Vargas R
    Gynecol Oncol; 2020 Dec; 159(3):699-705. PubMed ID: 32950250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of elevated pretreatment serum levels of CEA and CA-125 in epithelial ovarian cancer.
    Lin YH; Wu CH; Fu HC; Chen YJ; Chen YY; Ou YC; Lin H
    Cancer Biomark; 2020; 28(3):285-292. PubMed ID: 32390605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients.
    Heinze K; Rengsberger M; Gajda M; Jansen L; Osmers L; Oliveira-Ferrer L; Schmalfeldt B; Dürst M; Häfner N; Runnebaum IB
    Clin Epigenetics; 2021 Jan; 13(1):15. PubMed ID: 33482905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
    Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
    [No Abstract]   [Full Text] [Related]  

  • 19. Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer.
    Prahm KP; Høgdall C; Karlsen MA; Christensen IJ; Novotny GW; Høgdall E
    PLoS One; 2018; 13(11):e0207319. PubMed ID: 30475821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
    Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
    J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.